We offer a customized synthesis of mRNA for screening to preclinical studies. Our high-quality mRNA transcripts are ideal for functional studies, therapeutics, diagnostics, and vaccine production. IVT is the method of choice to produce long and stable RNA molecules such as mRNA, guide RNA, SaRNA , or long RNA when chemical synthesis is not possible.
Irrespective of scale, mRNA molecules go through rigorous in-process and final quality checks through a set of standard and customized analytical methods. Our mRNA processes are flexible and can be customized as per client needs.
Our mRNA services are integrated to high-quality plasmid DNA production, processing enzymes, and other reagent generations. We provide high-throughput codon-optimized gene synthesis and cloning. We perform E. coli clone development, cell banking, E. coli fermentation, and plasmid purification.
mRNA formulation: We support small scale mRNA formulation development and characterization.
In vitro transcription
- Sequence design, gene synthesis, and cloning
- RNA transcripts from plasmids, PCR products, and cDNA
- Conventional and Self-amplifying RNA (SaRNA)
- Flexibility to choose transcriptional promoter (T7 or SP6)
- Normal unmodified mRNA synthesis
- Use of modified bases in mRNA transcripts (Pseudo UTP etc.)
- Several strategies for 5’ capping such as co-translational capping with Anti Reverse Cap Analog (ARCA)
- Post-translational vaccinia capping
- Options to choose from Cap0 and Cap1
- Template-derived poly A tail or enzymatic incorporation in the IVT mRNA template
- Optimization of mRNA translation and stability
Purification
- Well-characterized in RNAse free environment
- High-quality plasmid purification, characterization, and IVT template preparation
- Method optimization for gram quantity
- Plasmid DNA purification and characterization
- Purification using lithium chloride precipitation and chromatography
Analytical control
- Batch-to-batch consistency of the IVT mRNA
- Bioanalyzer
- Purity (tape station)
- Length confirmation
- Sequence confirmation by cDNA
- Capping efficiency by mass-spec
- Endotoxin measurement
- SE-HPLC
- DOT-BLOT
- Immunogenicity testing for vaccine candidates
Why Aurigene mRNA Services?
Customized screening and scaling up strategies
In vitro transcription, purification, and quality controls
Customized formulation
Modernized state-of-the-art facility
Adaptable, scalable and high-quality
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
OCTOBER 01, 2024
PROTACs: Research for a life without cancer
PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Case study: Tackling CYP 2C9 inhibition challenges
The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...
Read More
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2022
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market